Summit Therapeutics (MEX:SMMT) ROCE %: -143.17% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics ROCE %?

Summit Therapeutics MEX:SMMT 30 ROCE % is -143.17% as of Jun. 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Summit Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2026 was -143.17%.

Summit Therapeutics  (MEX:SMMT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Summit Therapeutics ROCE % Related Terms

Summit Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics ROCE % Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -105.28 -20.73 -132.87 -78.40 -190.33

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -707.40 -396.66 -199.50 -125.76 -143.17
MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics ROCE % Calculation

Summit Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-19437.801/( ( (9083.909 - 870.288) + (13525.558 - 1314.2) )/ 2 )
=-19437.801/( (8213.621+12211.358)/ 2 )
=-19437.801/10212.4895
=-190.33 %

Summit Therapeutics's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-15389.74/( ( (11682.593 - 1501.511) + (13124.876 - 1807.123) )/ 2 )
=-15389.74/( ( 10181.082 + 11317.753 )/ 2 )
=-15389.74/10749.4175
=-143.17 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -143.17% mean?
Summit Therapeutics (MEX:SMMT) has a ROCE % of -143.17% as of Jun. 2026.
Is Summit Therapeutics' ROCE % too high?
Summit Therapeutics' current ROCE % is -143.17%. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' ROCE % compare to TECH and AXSM?
Summit Therapeutics' ROCE % of -143.17% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Summit Therapeutics's current ROCE % is -143.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current ROCE % of -143.17%. The current ROCE % is -143.17%. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current ROCE % is -143.17% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price